FINWIRES · TerminalLIVE
FINWIRES

$BMY

49 stories mentioning BMYUpdated 3d ago

Every FINWIRES story that references BMY, newest first.

What are analysts saying about BMY?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on BMY?

Insider Trading

Bristol Myers Squibb Insider Sold Shares Worth $403,498, According to a Recent SEC Filing

Cristian Massacesi, Executive Vice President, Chief Medical Officer and Head of Development, on September 09, 2026, sold 6,249 shares in Bristol Myers Squibb (BMY) for $403,498. Following the Form 4 filing with the SEC, Massacesi has control over a total of 18,748 common shares of the company, with 18,748 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/14272/000208017626000006/xslF345X05/wk-form4_1789072637.xml

$BMY
Wire

Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says

Cytokinetics (CYTK) likely has the upper hand in its patent dispute with Bristol-Myers Squibb (BMY) related to a patent for methods of treatment with cardiac myosin inhibitors, or CMIs, RBC Capital Markets said in a note Thursday.The investment firm said it hosted a call with a legal expert on the declaratory judgment filing by Cytokinetics against a Bristol-Myers Squibb patent for methods of treatment with CMIs. The investment firm added that the preemptive declaratory judgment seeks to prevent potential infringement claims by Bristol-Myers Squibb.RBC said its legal expert believes Cytokinetics has the upper hand given the way aficamten's label is written, which could allow the company freedom to operate, although Bristol-Myers Squibb could seek to have the case dismissed for lack of standing.RBC said, however, that a resolution for the case may be "years away" and investors should focus on Cytokinetics' near-term dynamics.The investment firm said it remains bullish on the launch of Cytokinetics' aficamten, which may be on track to reach $135 million in 2026 sales, and it expects Cytokinetics' shares to start better reflecting the commercial opportunity as well as a future label expansion.RBC has an outperform rating on Cytokinetics and a $112 price target.Price: $74.62, Change: $+0.51, Percent Change: +0.69%

$BMY$CYTK
Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.2% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1.1%.The iShares Biotechnology ETF (IBB) was down 1%.In corporate news, Bristol Myers Squibb (BMY) told regulators, researchers and patient groups in early June that it had paused trials of its CAR-T treatment zola-cel in autoimmune disorders over potentially life-threatening side effects, The Wall Street Journal reported. Bristol Myers Squibb shares were falling 2%.Novo Nordisk's (NVO) charitable foundation and its Quantum Foundry Copenhagen company are planning to set up a new 5,300 square meter quantum chip production facility in Copenhagen, the organizations said. Novo shares were down 2.2%.Immuron (IMRN) shares surged 57% after it said Friday it has signed an exclusive distribution agreement with Sweden's Calmino Group to launch PROIBS, a digestive-health medical device used for abdominal pain and bloating.Tarsus Pharmaceuticals (TARS) shares rose past 9% after the company said it has completed its acquisition of retinal disease-focused biotech Alkeus Pharmaceuticals.

$BMY$IMRN$NVO$TARS
Sectors

Sector Update: Healthcare Stocks Decline Friday Afternoon

Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 1.1%.The iShares Biotechnology ETF (IBB) was down 1%.In corporate news, Bristol Myers Squibb (BMY) told regulators, researchers and patient groups in early June that it had paused trials of its CAR-T treatment zola-cel in autoimmune disorders over potentially life-threatening side effects, The Wall Street Journal reported. Bristol Myers Squibb shares were falling 2.2%.Novo Nordisk's (NVO) charitable foundation and its Quantum Foundry Copenhagen company are planning to set up a new 5,300 square meter quantum chip production facility in Copenhagen, the organizations said. Novo shares were down 2.1%.Intellia Therapeutics (NTLA) shares added 0.8% after it said Friday it entered a $400 million non-dilutive senior secured term loan facility with OrbiMed to support clinical and commercial milestones.Immuron (IMRN) shares surged 41% after the company announced Friday an exclusive distribution agreement for Probis in the US with Calmino.

$BMY$IMRN$NTLA$NVO
Sectors

Sector Update: Healthcare

Healthcare stocks declined Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 1%.The iShares Biotechnology ETF (IBB) was down 1%.In corporate news, Bristol Myers Squibb (BMY) told regulators, researchers and patient groups in early June that it had paused trials of its CAR-T treatment zola-cel in autoimmune disorders over potentially life-threatening side effects, The Wall Street Journal reported. Bristol Myers Squibb shares were falling 2.1%.

$BMY
Sectors

Sector Update: Healthcare Stocks Mixed Pre-Bell Friday

Healthcare stocks were mixed pre-bell Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.2% and the iShares Biotechnology ETF (IBB) 0.1% higher.Novo Nordisk's (NVO) charitable foundation and its Quantum Foundry Copenhagen company are planning to set up a new 5,300 square meter quantum chip production facility in Copenhagen, the organizations said. Shares of Novo Nordisk were down more than 2% premarket.Bristol Myers Squibb (BMY) told regulators, researchers and patient groups in early June that it had paused trials of its CAR-T treatment zola-cel in autoimmune disorders over potentially life-threatening side effects, The Wall Street Journal reported. Bristol Myers Squibb stock was down 1% pre-bell.Ionis Pharmaceuticals (IONS) shares were 0.8% higher after the company said the US Food and Drug Administration approved zanvastrotm, or zilganersen, to treat Alexander disease in pediatric and adult patients.

$BMY$IBB$IONS$NVO$XLV
Sectors

Sector Update: Healthcare Stocks Rise Late Afternoon

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.2%.The iShares Biotechnology ETF (IBB) increased 0.5%.In corporate news, Eli Lilly (LLY) shares rose 4.7% after it posted higher Q2 non-GAAP earnings and revenue in addition to raising its 2026 sales guidance. Separately, CVS Health (CVS) said Wednesday it revamped its direct-to-consumer weight management program, lowering the cost of virtual visits and expanding access to GLP-1 medications through a collaboration with Lilly. CVS shares were down 3.8%.Novo Nordisk (NVO) said Wednesday it won a preliminary injunction in the Netherlands against Ceban Ziekenhuisfarmacie in a patent-infringement case involving its compounded semaglutide nasal spray. Novo shares added 0.6%.AstraZeneca (AZN) and Bristol Myers Squibb (BMY) are not engaged in discussions over a potential merger, Reuters reported Wednesday, citing a senior source close to the matter. AstraZeneca shares rose 3.5%, and Bristol Myers Squibb fell 3.2%.Charles River Laboratories (CRL) on Wednesday reported fiscal Q2 non-GAAP earnings and sales above market expectations and raised its 2026 non-GAAP EPS guidance. Its shares jumped 11%.

$AZN$BMY$CRL$CVS$LLY$NVO
Sectors

Sector Update: Healthcare Stocks Advance Wednesday Afternoon

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index rising 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1%.The iShares Biotechnology ETF (IBB) increased 0.9%.In corporate news, Eli Lilly (LLY) shares rose 3.7% after it posted higher Q2 non-GAAP earnings and revenue in addition to raising its 2026 sales guidance. Separately, CVS Health (CVS) said Wednesday it revamped its direct-to-consumer weight management program, lowering the cost of virtual visits and expanding access to GLP-1 medications through a collaboration with Lilly. CVS shares were down 4.9%.Novo Nordisk (NVO) said Wednesday it won a preliminary injunction in the Netherlands against Ceban Ziekenhuisfarmacie in a patent-infringement case involving its compounded semaglutide nasal spray. Novo shares rose 1.3%.AstraZeneca (AZN) and Bristol Myers Squibb (BMY) are not engaged in discussions over a potential merger, Reuters reported Wednesday, citing a senior source close to the matter. AstraZeneca shares rose nearly 4%, and Bristol Myers Squibb fell 3.5%.

$AZN$BMY$CVS$LLY$NVO
Wire

Update: Market Chatter: AstraZeneca, Bristol Myers Not Pursuing Merger Talks

(Updates with responses from the companies in the third paragraph.)AstraZeneca (AZN) and Bristol Myers Squibb (BMY) are not engaged in discussions over a potential merger, Reuters reported Wednesday, citing a senior source close to the matter."There is no deal between AstraZeneca and BMS. There never was a deal to be done, and there are no discussions between the companies," the source told Reuters.AstraZeneca and Bristol Myers Squibb declined to comment on the matter.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $162.62, Change: $+7.00, Percent Change: +4.50%

$AZN$BMY
Research

Argus Upgrades Bristol-Myers Squibb to Buy From Hold, Price Target is $75

Bristol-Myers Squibb Company (BMY) has an average rating of overweight and mean price target of $66.04, according to analysts polled by FactSet.

$BMY
Wire

Bristol Myers Squibb Potential Deal With AstraZeneca Seen Unlikely as Shareholder Views Diverge, RBC Says

Bristol Myers Squibb's (BMY) reported merger discussions with AstraZeneca (AZN) will unlikely result in a transaction as AstraZeneca's shareholders could broadly oppose the combination, RBC Capital Markets said in a Tuesday note.According to the note, investors generally viewed the talks as credible following the companies' silence after the media report, but most considered the probability of a deal to be low.AstraZeneca shareholders questioned the rationale for the transaction and expressed concerns about growth, while several viewed the report as a trial balloon that could ultimately be abandoned, the analysts said.RBC also said Bristol Myers investors were generally constructive toward a transaction but the support depended ona substantial premium and clear value creation. Investors indicated a 40% to 50% premium could be needed to meet return thresholds, while upcoming data for Milvexian and Cobenfy could strengthen Bristol Myers' standalone position and negotiating leverage.RBC maintained its sector perform rating and $64 price target on Bristol Myers Squibb.Price: $64.48, Change: $-0.99, Percent Change: -1.51%

$AZN$BMY
Merck, Pfizer Lift Full-Year Sales Outlooks Following Second-Quarter Beats
US Markets

Merck, Pfizer Lift Full-Year Sales Outlooks Following Second-Quarter Beats

Merck (MRK) and Pfizer (PFE) raised their respective full-year sales outlooks on Tuesday, as both pharmaceutical giants logged better-than-expected sales for the second quarter.For 2026, Merck now expects revenue of $66.3 billion and $67.3 billion, compared with its prior guidance of $65.8 billion to $67.0 billion and the FactSet-polled consensus of $66.86 billion. The company cut its full-year adjusted earnings estimate to a range of $2.66 and $2.76, from $5.04 to $5.16, to account for charges of $2.43 per share for the acquisition of Terns Pharmaceuticals (TERN). Analysts expect non-GAAP EPS of $2.79.For the June quarter, Merck's sales rose 5% year over year to $16.61 billion, topping the consensus of $16.37 billion. The company swung to a second-quarter non-GAAP loss $0.13 per share due to the Terns acquisition charge, from EPS of $2.13 a year earlier, while analysts expected a loss of $0.27.In May, the company announced completion of the acquisition of Terns and flagged the one-time charge."We delivered growth in the quarter led by continued strength in oncology and animal health, along with increasing contributions from our diverse and compelling new products across an array of therapeutic areas," Merck Chief Financial Officer Caroline Litchfield said at an earnings call, according to a FactSet transcript.Pfizer narrowed its full-year revenue outlook to between $60.5 billion to $62.5 billion from the previous range of $59.5 billion to $62.5 billion, reflecting a $500 million increase at the midpoint. The company maintained its adjusted EPS guidance of $2.80 to $3. At midpoint the estimates are both below the consensus forecasts of $61.77 billion and $2.94, respectively.Pfizer's second-quarter sales grew 3% year over year to $15.03 billion, while analysts projected $14.4 billion. Adjusted EPS fell to $0.77 from $0.78 a year earlier but exceeded the Street's $0.68 forecast."Our launched and acquired products performed well, our obesity program is advancing with meaningful momentum and our oncology portfolio remains a source of strength," Pfizer CEO Albert Bourla said in a statement.Last week, AbbVie (ABBV) lowered its full-year earnings guidance to account for the expected dilution from its planned acquisition of Apogee Therapeutics (APGE), despite reporting stronger-than-expected second-quarter results.Last month, Johnson & Johnson (JNJ) raised its full-year outlook after reporting better-than-expected second-quarter results, driven by growth in its innovative medicine and medical device businesses. Bristol-Myers Squibb (BMY) also raised its full-year guidance after reporting second-quarter results.Merck shares of were advancing by 0.3% in Tuesday morning trade, with the stock up 22% so far this year. Pfizer was down 0.4% intraday and is up about 0.1% since the start of the year.Price: $128.40, Change: $+0.63, Percent Change: +0.49%

$ABBV$APGE$BMY$JNJ$MRK$PFE$TERN
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index falling 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1%.The iShares Biotechnology ETF (IBB) shed 0.2%.In corporate news, Integer (ITGR) agreed to be acquired and taken private by investment firm KKR (KKR) in an all-cash deal with an enterprise value of about $5.7 billion. Integer shares rose 2.6%.AstraZeneca (AZN) is in talks with Bristol Myers Squibb (BMY) about a potential combination that would create a company valued at almost $400 billion, the Financial Times reported Sunday. AstraZeneca shares slumped 6.8%, and Bristol Myers rose 0.4%.Lantheus Holdings (LNTH) agreed to be acquired and taken private by Curium for up to $8 billion. Lantheus shares rose 1.7%.Krystal Biotech (KRYS) shares dropped 8.4% after its Q2 product revenue fell short of analysts' estimates.

$AZN$BMY$ITGR$KRYS$LNTH
Asia Markets

Update: US Equity Indexes Rise Amid Rally in Communication Services; Crude Oil Slides With Treasury Yields

US equity indexes rose after midday Monday amid strong gains in communications services, while a slide in government bond yields accompanied a drop in crude oil futures.The Nasdaq Composite jumped 2.2% to 25,923.9, with the S&P 500 up 1.4% to 7,596.8 and the Dow Jones Industrial Average higher by 1.1% to 53,071.2.Communication services surged 4.5%, topping sector charts, followed by a rise in consumer discretionary and technology. Energy, healthcare and consumer staples led decliners."Iranian Leadership is unbelievably duplicitous!" President Donald Trump said in a social media post Monday, reverting to lashing out at Iran after canceling a planned attack against the Islamic Republic last Saturday because the "perimeters of a deal has been agreed to.""Nothing gets through to Iran unless we want it to, and nothing will get through unless a Deal, or Total Surrender, is accomplished," the US president said, referring to the US blockade of Iranian ports. "Whether Iran wants to admit it or not, we are, in fact, talking of a solution to a problem that they have caused, for decades."Iran's Foreign Ministry Spokesman Esmaeil Baghaei said no negotiations with the US were underway and no meetings were scheduled, Reuters reported.Oman and Iran have been negotiating over a new maritime route through the Strait of Hormuz, which borders both their territorial waters, Al Jazeera, a Middle Eastern broadcaster, reported. Sunday night, Iran's Foreign Minister Abbas Araghchi told the Iranian cabinet in a report that negotiations between Tehran and Muscat were "on the way to being finalized".The front-month US West Texas Intermediate crude oil slumped 5.4% to $80.08 a barrel, and global benchmark North Sea Brent dropped 4.9% to $83.66 a barrel.Most US Treasury yields declined, with the 10-year trading down 5.5 basis points to 4.69%, retreating from the 52-week high touched late last week. The two-year yield dropped 3.1 basis points to 4.26%.In precious metal markets, gold futures slipped 0.4% to $4,090.5, while silver futures were unchanged at $57.77.In economic news, the Institute for Supply Management's US manufacturing index rose to 55.6 in July from 53.3 in June, compared with expectations for 53.9 in a Bloomberg-compiled survey. This is the highest reading since May 2022, ISM said.The S&P Global US manufacturing index for July was revised upward to 53.9 from the flash reading of 53.8, compared with expectations for no revision in a survey compiled by Bloomberg.In company news, Alibaba (BABA) launched Qwen3.8-Max, its latest large language model, and plans to release the model's open weights next week alongside Qwen3.8-27B.Bristol Myers Squibb (BMY) is in talks with AstraZeneca (AZN) about a potential combination that would create a pharmaceutical company valued at nearly $400 billion, the Financial Times reported.Marriott International (MAR) reported Q2 revenue below estimates amid headwinds from the Middle East conflict, and offered a downbeat Q3 earnings outlook. Shares slumped 6.3%, among the worst performers on the Nasdaq and the S&P 500.

Dow JonesNasdaq CompositeS&P 500$AZN$BABA$BMY$MAR
Sectors

Sector Update: Healthcare Stocks Decline Monday Afternoon

Healthcare stocks declined Monday afternoon, with the NYSE Healthcare Index falling 1% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 0.5%.The iShares Biotechnology ETF (IBB) shed 0.7%.In corporate news, Integer (ITGR) agreed to be acquired and taken private by investment firm KKR (KKR) in an all-cash deal with an enterprise value of about $5.7 billion. Integer shares rose 2.7%.AstraZeneca (AZN) is in talks with Bristol Myers Squibb (BMY) about a potential combination that would create a company valued at almost $400 billion, the Financial Times reported Sunday. AstraZeneca shares slumped 7.5%, and Bristol Myers dropped 0.8%.Lantheus Holdings (LNTH) agreed to be acquired and taken private by Curium for up to $8 billion. Lantheus shares rose 2.2%.

$AZN$BMY$ITGR$LNTH
Wire

Top Midday Stories: Amazon Market Cap Hits $3 Trillion; AstraZeneca, Bristol Myers Squibb Reportedly Discuss $400 Billion Combination

All three major US stock indexes were up in late-morning trading Monday after President Donald Trump said Sunday he cancelled a planned attack on Iran.In company news, Amazon.com (AMZN) shares rose Monday morning, bringing the tech giant's market capitalization above $3 trillion for the first time. Amazon shares were up 5.2% around midday.AstraZeneca (AZN) is in talks with Bristol Myers Squibb (BMY) about a potential combination that would create a company valued at nearly $400 billion, the Financial Times reported Sunday, citing people familiar with the matter. The companies have held discussions in recent months, though a deal could still be delayed or fail to materialize, the report said, citing the people. AstraZeneca shares were down 9.4%, while Bristol Myers Squibb shares were down 0.7%.Lantheus (LNTH) said Monday it signed a definitive agreement to merge with a unit of Curium US Holdings in a deal valued at up to $8 billion. The buyer will pay $102.50 per Lantheus share in cash at closing and up to $12 per share in future milestone-based cash payments through 2030, the company said. The deal is expected to close in H1 2027, subject to regulatory and shareholder approvals. Lantheus shares were up 2.8%.Visa (V) said Monday it has agreed to acquire fraud intelligence company BioCatch for $2.4 billion in cash. The deal will likely close by the end of Visa's fiscal Q2 2027, the company said. Visa shares were up 0.1%.ArcelorMittal (MT) said Monday it has expanded its partnership with Microsoft (MSFT) to implement artificial intelligence tools in its international business processes. The mining company will adopt Microsoft Azure as its primary cloud infrastructure to update core information technology frameworks and centralize data, it said. ArcelorMittal shares were up 1.4%, while Microsoft shares were up 4.9%.JPMorgan Chase (JPM) said Monday it plans to spend $750 billion through 2035 to increase the housing supply and support home ownership in the US. JPMorgan shares were up 0.2%.GameStop (GME) has agreed to exchange about $1.4 billion of its outstanding 0% convertible senior notes due 2030 and 2032 for its class A common stock without the use of cash. Noteholders are exchanging around $400 million of the 2030 notes and $1 billion of the 2032 notes, the company said. The exchange is expected to close around Sept. 23. GameStop shares were down 12.6%.Price: $285.78, Change: $+14.20, Percent Change: +5.23%

$AMZN$AZN$BMY$GME$JPM$LNTH$MSFT$MT$V
Sectors

Sector Update: Healthcare Stocks Rise Pre-Bell Monday

Healthcare stocks were rising pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 1.2% higher and the iShares Biotechnology ETF (IBB) advancing by 0.8%.AstraZeneca (AZN) is in talks with Bristol Myers Squibb (BMY) about a potential combination that would create a pharmaceutical company valued at nearly $400 billion, the Financial Times reported, citing unnamed people familiar with the matter. Astrazeneca stock was 7% lower, while Bristol Myers Squibb shares were up more than 3% premarket.Supernus Pharmaceuticals (SUPN) and Indivior Pharmaceuticals (INDV) said they will merge in a tax-free, all-stock deal. Shares of Supernus Pharmaceuticals were up more than 14% and Indivior Pharmaceuticals stock advanced past 1% pre-bell.KKR (KKR) entered into a definitive agreement to acquire Integer (ITGR) through affiliated funds in an all-cash transaction at an enterprise value of $5.7 billion, the companies said. Integer shares were up more than 2% premarket.

$AZN$BMY$IBB$INDV$ITGR$KKR$SUPN$XLV
Asia Markets

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Amid US-Iran Truce Hopes

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.5%, and the actively traded Invesco QQQ Trust (QQQ) was 0.2% higher in Monday's premarket activity as traders hope for a US-Iran truce.US stock futures were higher, with S&P 500 Index futures up 0.5%, Dow Jones Industrial Average futures advancing 0.9%, and Nasdaq futures gaining 0.3% before the start of regular trading.July's manufacturing data from S&P Global will be released at 9:45 am ET.The ISM's manufacturing report and June's construction data will be released at 10 am ET.In premarket activity, bitcoin was down by 1.4%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.8% lower, Ether ETF (EETH) retreated 1.7%, and Bitcoin & Ether Market Cap Weight ETF (BETH) declined 0.1%.Power Play:ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.8%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was down 0.2%, and the iShares US Consumer Staples ETF (IYK) was 0.9% lower. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increased 1.1%. The VanEck Retail ETF (RTH) and the State Street SPDR S&P Retail ETF (XRT) were inactive.Alibaba (BABA) shares were up more than 4% pre-bell after the company said in a social media post that it launched Qwen3.8-Max, its latest large language model, and plans to release the model's open weights next week alongside Qwen3.8-27B.Winners and Losers:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 1.1%, the Vanguard Health Care Index Fund (VHT) was up 0.8%, while the iShares US Healthcare ETF (IYH) increased 0.04%. The iShares Biotechnology ETF (IBB) was 0.4% higher.AstraZeneca (AZN) stock was down more than 4% premarket, while Bristol Myers Squibb (BMY) gained 4% after Financial Times reported Sunday that the companies are in talks about a potential combination that would create a pharmaceutical company valued at nearly $400 billion.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) retreated 0.5%, the iShares US Technology ETF (IYW) was flat, and the iShares Expanded Tech Sector ETF (IGM) was up 0.1%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) was 1.5% lower, while the iShares Semiconductor ETF (SOXX) fell by 2.4%.Parsons (PSN) shares were up more than 2% in premarket activity after the company said it will serve as the lead designer for the Interstate 526 Long Point Road Interchange Improvements project in South Carolina.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.8%. Direxion Daily Financial Bull 3X Shares (FAS) was up 2.3%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 2.3% lower.KKR (KKR) shares were up more than 1% in early hours activity after the company entered into a definitive agreement to acquire Integer (ITGR) through affiliated funds in an all-cash transaction at an enterprise value of $5.70 billion. Integer stock was 2.6% higher.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.6%, while the Vanguard Industrials Index Fund (VIS) was up 0.6% and the iShares US Industrials ETF (IYJ) was 0.4% higher.Boeing (BA) stock was up more than 1% before the opening bell after the company said it has delivered Somon Air's first 737 Max aircraft.EnergyThe iShares US Energy ETF (IYE) was inactive, while the State Street Energy Select Sector SPDR ETF (XLE) was down by 1.2%.Shell (SHEL) stock was down more than 1% before market open after the company agreed to sell its European onshore renewables portfolio to TotalEnergies (TTE). TotalEnergies' shares were 0.6% lower.CommoditiesFront-month US West Texas Intermediate crude oil fell by 6.8% to $78.92 per barrel on the New York Mercantile Exchange. Natural gas was up 0.8% at $2.77 per 1 million British Thermal Units. The United States Oil Fund (USO) decreased by 6.8%, while the United States Natural Gas Fund (UNG) was 0.5% higher.Gold futures for November advanced by 0.2% to $4,114.80 an ounce on the Comex. Silver futures gained by 0.7% to reach $58.18 an ounce. SPDR Gold Shares (GLD) was up by 0.1%, and the iShares Silver Trust (SLV) fell by 0.4%.

Dow JonesNasdaq CompositeS&P 500$AZN$BA$BABA$BETH$BITO$BMY$EEM$EETH$EXI$FAS$FAZ$GLD$IBB$IGM$IGV$IPK$ITGR$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$KKR$PMR$PSN$QQQ$RTH$SHEL$SLV$SOXX$SPY$TTE$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Sectors

Sector Update: Healthcare

Healthcare stocks were rising pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 1.2% higher and the iShares Biotechnology ETF (IBB) advancing by 0.5%.AstraZeneca (AZN) is in talks with Bristol Myers Squibb (BMY) about a potential combination that would create a pharmaceutical company valued at nearly $400 billion, the Financial Times reported, citing unnamed people familiar with the matter. Astrazeneca stock was 7% lower, while Bristol Myers Squibb shares were up more than 4% premarket.

$AZN$BMY
Asia Markets

Update: Middle East Diplomacy Optimism, Oil Price Decline Lift US Equity Futures Pre-Bell

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock movements.)US equity futures were higher pre-bell Monday as the US moved toward diplomacy in its war with Iran and oil prices fell.Dow Jones Industrial Average futures were 1.1% higher, S&P 500 futures were up 0.5%, and Nasdaq futures were 0.2% higher.President Donald Trump said in a post Sunday on Truth Social that he had cancelled an attack on Iran. "We have just been asked by Iran, and other Middle Eastern Countries, to hold off any attack in that the perimeters of a deal has been agreed to," Trump said, adding that the deal would include the complete opening of the Strait of Hormuz and "an end to Iran's nuclear threat."Palantir Technologies (PLTR) is expected to report its Q2 earnings after the market closes. Analysts polled by FactSet expect earnings of $0.34 per share on revenue of $1.81 billion.Expected to report later in the week are SpaceX (SPCX), Advanced Micro Devices (AMD), Sandisk (SNDK), Western Digital (WDC), Caterpillar (CAT), ConocoPhillips (COP), Eli Lilly (LLY), Uber Technologies (UBER), and Berkshire Hathaway (BRK.A, BRK.B).Oil prices were lower, with front-month global benchmark North Sea Brent crude down 5.6% at $82.97 per barrel and US West Texas Intermediate crude 6.7% lower at $78.97 per barrel.The final S&P Global manufacturing purchasing managers index for July, due at 9:45 am ET, is seen at 53.8, unchanged from its prior value, according to estimates compiled by Bloomberg.The July Institute for Supply Management's manufacturing index, due at 10 am ET, is projected at 53.9, up from 53.3 in the previous month. The June construction spending report is also due at 10 am ET.In other world markets, Japan's Nikkei closed 0.9% lower, Hong Kong's Hang Seng ended 0.5% higher, and China's Shanghai Composite finished 0.6% lower. Meanwhile, the UK's FTSE 100 was down 0.1%, and Germany's DAX index was 1.3% higher in Europe's early afternoon session.In equities, Alibaba (BABA) shares rose 3.6% after the company said in a social media post that it launched Qwen3.8-Max, its latest large language model, and plans to release the model's open weights next week alongside Qwen3.8-27B. Boeing (BA) stock was up 1.9% after the company said it delivered Somon Air's first 737 Max aircraft. BNP Paribas also upgraded Boeing's stock rating to outperform from underperform.Bristol Myers Squibb (BMY) shares were up 4.2% after a Financial Times report that the company was in talks with Astrazeneca (AZN) about a potential combination that would create a pharmaceutical company valued at nearly $400 billion. On the other hand, Astrazeneca stock was down 6.2%.On the losing side, BP (BP) shares fell 3.2% after the company completed the divestment of its Gelsenkirchen complex to independent refiner Klesch Group. Marriott International (MAR) stock was down 3.8% after the company reported lower-than-expected Q2 revenue and issued guidance for Q3 adjusted EPS that fell short of analysts' consensus.

Dow JonesNasdaq CompositeS&P 500$AMD$AZN$BA$BABA$BMY$BP$BRK.A$BRK.B$CAT$COP$LLY$MAR$PLTR$SNDK$SPCX$UBER$WDC

Showing 1-20 of 49

Track with the FINWIRES app suite

FolioX
FolioX
Track BMY in your portfolio
WheelAI
WheelAI
Analyze BMY options with the wheel strategy
StockInsider
StockInsider
See market sentiment on BMY